Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Peking University Cancer Hospital & Institute
Modality
antibody_drug_conjugate
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07417241CT.gov SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | — | Not Yet Recruiting | — | — | — |
NCT07459673CT.gov HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission | — | Recruiting | — | — | — |
NCT07294508CT.gov A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT07281001CT.gov A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients | — | Recruiting | — | — | — |
NCT07035353CT.gov A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06548178CT.gov T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT05593094CT.gov A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · HER2 Positive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Dxd (this asset) | Peking University Cancer Hospital & Institute | P2/3 | B · 63 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Trastuzumab | SWOG Cancer Research Network | P4 | BB |
| Ribociclib | Danish Breast Cancer Cooperative Group | P3 | BB |
| Vinorelbine Ditartrate | Fudan University | P3 | BB |
| Capecitabine | MedSIR | P4 | BB |
| Cyclophosphamide | National University Hospital, Singapore | P3 | BB |
| Docetaxel | Ohio State University Comprehensive Cancer Center | P3 | BB |
| Epirubicin | Ohio State University Comprehensive Cancer Center | P3 | BB |
+42 more in the HER2 Positive Breast Carcinoma cohort
Other indications for T-Dxd
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm In The Brain | — | P2 | CCC · 55 |
| Estrogen-Receptor Positive Breast Cancer | — | P2 | CCC · 53 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CCC · 52 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. T-Dxd in HER2 Positive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/t-dxd-her2-positive-breast-carcinoma-32836
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →